Sign up to save your podcasts
Or
Share Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.
CME information and select publications here.
View all episodes
By Dr. Neil Love
4.4
6262 ratings
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.
CME information and select publications here.
More shows like Breast Cancer Update
View all
JAMA Editors' Summary
141 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
500 Listeners
Lung Cancer Update
32 Listeners
Hematologic Oncology Update
75 Listeners
Prostate Cancer Update
14 Listeners
Gastrointestinal Cancer Update
17 Listeners
Gynecologic Oncology Update
13 Listeners
Dermatologic Oncology Update
0 Listeners
Research To Practice | Oncology Videos
118 Listeners
ASCO Daily News
58 Listeners
Mayo Clinic Talks
291 Listeners
The Curbsiders Internal Medicine Podcast
3,355 Listeners
The ONS Podcast
198 Listeners
The Clinical Problem Solvers
510 Listeners
Oncology Today with Dr Neil Love
58 Listeners
Two Onc Docs
190 Listeners
Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing
0 Listeners